BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 2601083)

  • 1. [Clinical evaluation of serum TAC-41 in various digestive cancers].
    Sato S; Yamanaka T; Kimura K
    Rinsho Byori; 1989 Nov; 37(11):1259-62. PubMed ID: 2601083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Tumor markers--personal experience. The use of tumor markers for cancer of digestive organs].
    Ishii M
    Gan To Kagaku Ryoho; 1991 May; 18(6):1059-65. PubMed ID: 1709347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Diagnostic value of serum CA 19-9 determination in digestive tract cancer].
    Chen SB
    Zhonghua Zhong Liu Za Zhi; 1990 Jan; 12(1):58-60. PubMed ID: 2364873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CA 50: a tumor marker for gastrointestinal malignancies.
    Bunworasate U; Voravud N
    J Med Assoc Thai; 1995 May; 78(5):255-70. PubMed ID: 7561549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Diagnostic usefulness of Ca 19-9 antigen in cancer of the pancreas and neoplasms of the pancreato-biliary intersection].
    Robles-Diáz G; Aceves G; Galván E
    Gac Med Mex; 1990; 126(2):78-82; discussion 82-3. PubMed ID: 2387490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Study on the clinical usefulness of NCC-ST-439 in cases of digestive tract cancer].
    Anzai K; Kurihara M; Izumi T
    Nihon Gan Chiryo Gakkai Shi; 1990 Jul; 25(7):1437-47. PubMed ID: 2212836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The diagnostic significance of carbohydrate antigen CA 19-9 in serum and pancreatic juice in pancreatic carcinoma.
    Chen YF; Mai CR; Tie ZJ; Feng ZT; Zhang J; Lu XH; Lu GJ; Xue YH; Pan GZ
    Chin Med J (Engl); 1989 May; 102(5):333-7. PubMed ID: 2509154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor markers CA 125, squamous cell carcinoma antigen, and carcinoembryonic antigen in patients with adenocarcinoma of the uterine cervix.
    Duk JM; Aalders JG; Fleuren GJ; Krans M; De Bruijn HW
    Obstet Gynecol; 1989 Apr; 73(4):661-8. PubMed ID: 2648225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antigens CA-50 and CA-242 in digestive tract and thyroid neoplasms].
    Pomorski L; Pasieka Z; Kołomecki K; Czyz W; Kołodziejczyk M; Wróbel B
    Wiad Lek; 1997; 50 Suppl 1 Pt 1():18-20. PubMed ID: 9446350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of the clinical usefulness of CA 19-9 and CA 50 in the diagnosis and monitoring of gastrointestinal cancers.
    Kokociñska D; Jarzab B; Król R; Ziaja K; Szejbak K; Kuśmierski S
    J Environ Pathol Toxicol Oncol; 1996; 15(2-4):283-7. PubMed ID: 9216823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Serum level of tumor markers (antigen Ca 19-9, CEA, ferritin) in digestive tumors. Their diagnostic usefulness].
    Jovin G; Stănel I; Popovici I; Oproiu A
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1988; 40(3):223-9. PubMed ID: 2904162
    [No Abstract]   [Full Text] [Related]  

  • 12. [The clinical value of tumor marker CA50 and CA242 in digestive tract cancer].
    Huang C; Bei L; Liu T
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1998 Aug; 20(4):285-8. PubMed ID: 11367693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Diagnostic value of a new serum marker of human digestive cancer: the carbohydrate antigen 19.9; comparison with the carcinoembryonic antigen].
    Olsson NO; Crimet-Montange D; Martin F
    Gastroenterol Clin Biol; 1985 Mar; 9(3):206-11. PubMed ID: 3859449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Serological test of carbohydrate antigen CA50 in patients with cancer of the digestive tract].
    Takami H; Furuuchi T; Ogata Y; Abe O
    Gan To Kagaku Ryoho; 1987 Feb; 14(2):495-501. PubMed ID: 3468885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Diagnostic usefulness and limitation of measuring pancreatic cancer associate antigen, SPan-1, in patients with pancreatic cancer].
    Satake K; Chung YS; Umeyama K; Takeuchi T; Kim YS
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):1139-46. PubMed ID: 2730018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor markers in pancreatic cancer. Sensitivity and specificity of CA 19-9.
    Safi F; Roscher R; Beger HG
    Hepatogastroenterology; 1989 Dec; 36(6):419-23. PubMed ID: 2613165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Evaluation of CA 15-3 radioimmunoassay].
    Takemori Y; Odani H; Watanabe H; Ohta H; Satomura Y; Okai T; Sawabu N; Mai M; Hattori N; Hashimoto T
    Gan To Kagaku Ryoho; 1987 Jan; 14(1):114-8. PubMed ID: 3467654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Basic and clinical evaluation of an immunoradiometric competitive inhibition assay for 2----6 sialyl Lewis a antigen--2. Evaluation of clinical significance].
    Imura H; Takahashi T; Matsuda T; Yoshida O; Ohkura H; Seitetsu Y; Seino Y; Ishii M; Kuwabara M; Ariyoshi Y
    Gan To Kagaku Ryoho; 1989 Jun; 16(6):2203-12. PubMed ID: 2660749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative study of mucin-like carcinoma-associated antigen (MCA), CA 125, CA 19-9 and CEA in patients with ovarian cancer.
    Koelbl H; Schieder K; Neunteufel W; Bieglmayer C
    Neoplasma; 1989; 36(4):473-8. PubMed ID: 2770933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A clinical evaluation of the CA 72-4 serum level as a possible tumor marker].
    Jibiki K; Takeda M; Abe H; Ito M; Odagiri E; Demura R; Demura H; Takizawa K
    Gan No Rinsho; 1990 Oct; 36(12):2146-52. PubMed ID: 2232183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.